FINWIRES · TerminalLIVE
FINWIRES

Wolfe Initiates Harmony Biosciences at Outperform With $60 Price Target

By

Harmony Biosciences (HRMY) has an average rating of overweight and mean price target of $47.36, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles